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RECEIVER OPERATOR CHARACTERISTICS OF THE SYSMEX HPC MEA-
SUREMENT USED TO INITIATE APHERESIS OF BLOOD HEMATOPOIETIC
PROGENITOR CELLS
Hamilton, E.S.1, Flowers, C.R.2, Vaughn, M.L.1, Minerley, M.1,
Waller, E.K.2 1Emory Healthcare Transfusion Medicine Program,
Emory University, Atlanta, GA; 2Winship Cancer Institute, Emory
University, Atlanta, GA.
Background: Hematopoietic progenitor cells (HPC) can be
mobilized into the peripheral blood by the administration of
G-CSF and/or GM-CSF and collected by apheresis for patients
who are candidates for high dose chemotherapy and autologous
stem cell transplantation. The initiation of apheresis is com-
monly based upon the number of CD34 cells/L in the blood,
using a ﬂow cytometric assay that typically requires 2 hours for
sample preparation, acquisition, and reporting results. The
availability of a new technology for rapidly measuring the con-
tent of hematopoietic progenitor cells in blood samples based
upon size and impedance (Sysmex™) prompted an evaluation of
how this method compares to the CD34 ﬂow cytometric assay.
Methods: Prospective analysis was performed on 100 samples
of cytokine mobilized peripheral blood from adult patients (ages
27-73) scheduled for collection of autologous HPC by aphere-
sis. The HPC content was assayed using the Sysmex™
XE2100L (performed by the apheresis staff), and by the clinical
lab using a dual platform BD FACScaliber™ and a modiﬁed
ISHAGE protocol. The study population consisted of lym-
phoma (n  32), multiple myeloma (n  27), Hodgkin’s disease
(n  9), and one patient each with CLL, germ cell cancer, and
amyloidosis. Results: The mean number of CD34 cells/L
determined using ﬂow cytometry was 57.6/L compared to
102.6/L using the Sysmex™, with a correlation coefﬁcient of
0.69. Of 71 patients being considered for apheresis, a mean
number of 14.7  106CD34 cells/kg were successfully col-
lected from 62 patients (87%). An analysis of the receiver
operating characteristics of the Sysmex assay, using the ﬂow
cytometric CD34 cell assay as a “gold-standard,” revealed that
initiation of apheresis when the Sysmex HPC threshold was
31 cells/L optimized the sensitivity and speciﬁcity of the test,
and was the best predictor of when patients should begin
apheresis collection (Table 1). The positive predictive value for
a Sysmex™ HPC result of 31/L was 80% (CD34 cell
counts of 	20/L); the negative predictive value for a Sysmex™
HPC of 31 cells/L was 88% (12% had CD34 cell counts
of 	 20/L). Conclusions: Use of the Sysmex™ method for
estimating HPC cell content of the peripheral blood is fast and
reliable, with excellent sensitivity and speciﬁcity compared to
ﬂow cytometry. Using the Sysmex™ HPC result to initiate
apheresis has reduced the average apheresis collection start time
more than an hour (Table 1).
Table 1. ROC of SysmexTM HPC Using CD34 	 20/L as the
Standard
HPC/L Sensitivity Specificity
>10 97.3% 52.8%
>20 91.9% 69.8%
>30 83.8% 84.9%
>40 78.4% 88.7%
>50 67.6% 92.5%
>60 62.2% 94.3%
>70 59.5% 94.3%
>80 56.8% 94.3%
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HIGH DOSE THERAPY VERSUS ORAL MAINTENANCE: RESULT OF HD-
CWS 96 STUDY FOR TREATMENT OF PATIENTS WITH METASTASIZED
SOFT TISSUE SARCOMA (STS)
Klingebiel, T.E.1, Boos, J.2, Hallmen, E.3, Beske, F.1, Treuner, J.2,
Koscielniak, E.2 1University Children’s Hospital, Frankfurt, Germany;
2University Children’s Hospital, Muenster, Germany; 3Olgahospital,
Stuttgart, Germany.
Objectives: We studied the efﬁcacy of high dose (HD) versus an
oral maintenance treatment (OMT) in patients with STS stage IV.
Methods: HD consisted of a tandem cycle of thiotepa (600 mg/
m2)  cyclophosphamide (4500 mg/m2) and melphalan (120 mg/
m2)  etoposide (1800 mg/m2). This treatment was optionally
compared with each 4 OMT cycles consisting of trofosfamide (10
days 275 mg/m2/d)  etoposide (10 days 225 mg/m2/d) and
trofosfamide (10 days 275 mg/m2/d)  idarubicin (10 days 45
mg/m2). Both groups were pretreated with the CEVAIE therapy
(HD 7, OMT 9 cycles) consisting of carboplatin, etoposide, vin-
cristine, actinomycin D, ifosfamide, and epirubicin. Results:Over-
all 753 patients were registered in CWS 96. From those 96 patients
fulﬁlled study inclusion criteria (primary stage IV, 22 years, and
intent to treat with study therapy). 45 were treated with HD, 51
with OMT. Whereas the study was not randomized, in the OMT
and HD groups the main risk parameters were equally distributed.
In the OMT group 15/51 (29%) fulﬁlled highest risk criteria (age
10 years and bone or bone marrow involvement), in the HD
group 16/45 (35%) respectively. However, in the HD-group 11/45
were alive at a median observation time of 24.6 months (24.4%), in
contrast to 26/51 OMT patients (50.9.%). Kaplan-Meier analysis
demonstrates an overall survival for the whole group of 0.27 (OMT
group: 0.31, HD group 0.20, log rank 0.0349). The proportional
hazard analysis for patients with rhabdomyosarcoma only (77.1%
of all patients) demonstrates an independent beneﬁt of oral main-
tenance treatment on outcome. Conclusions: Oral maintenance
therapy instead of tandem high dose therapy in patients with soft
tissue sarcoma stage IV seems to be a promising option for patients
with rhabdomyosarcoma.
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TARGETED RADIOTHERAPY IN THE CONDITIONING PRIOR TO HAEMA-
TOPOIETIC STEM CELL TRANSPLANTATION: RESULTS OF A PHASE I
TRIAL USING AN YTTRIUM-90-LABELLED ANTI-CD66 MURINE MONO-
CLONAL ANTIBODY DEMONSTRATING CONSISTENTLY HIGH BM UP-
TAKE
Orchard, K.H.1, Cooper, M.2, Lewington, V.3, Tristam, M.3,
Zivanovic, M.3, Thom, J.3, Quadri, S.4, Richardson, D.1, Causer, L.3,
Johnson, P.5 1Department of Haematology, Southampton, Hants, United
Kingdom; 2Department of Nuclear Medicine, St. Barthlemew’s Hospital,
London, United Kingdom; 3Department of Nuclear Medicine, SUHT,
Southampton, Hants, United Kingdom; 4National Institute for Health,
Bethesda, MD; 5Division of Cancer Sciences, SUHT, Southampton,
Hants, United Kingdom.
We report the results of a phase I clinical trial using an yttri-
um-90 (Y-90) radiolabelled anti-CD66 IgG1 murine monoclonal
antibody (TheraPharm GmbH) with conditioning therapy for pa-
tients receiving either an autologous or reduced intensity (RIC)
allogeneic stem cell transplant (SCT) for myeloma or AML. This
was a radiation dose escalation study with ﬁve patients at each
radiation dose level of 5, 10, 25 and 37.5 MBq/kilogram lean body
weight of recipient. Patients initially received indium-111-labelled
anti-CD66 for biodistribution and dosimetry. Patient Character-
istics: Ages 21-67 yrs (mean 56 yrs); 16 male, 4 female; disease
indication for transplant: myeloma 18, poor risk AML 2. Autolo-
gous transplant 16; RIC-allogeneic 4. Patients received the thera-
peutic dose of radiation on day 14, for autologous SCT they also
received melphalan 200 mg/m2 on day 2; allogeneic SCT pa-
tients received a combination of ﬂudarabine, melphalan and CAM-
PATH from day 8. Results: Excellent bone marrow targeting
was seen in all patients with a 2-10 fold excess of radiation deliv-
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ered to the bone marrow as compared with the liver. There was a
linear relationship between the infused dose of Y-90 and the
estimated radiation dose delivered to the BM. Mean absorbed
radiation doses were: bone marrow 10.23  1.8 cGy/MBq; liver
2.67  2.0 cGy/MBq; spleen 7.10  3.75 cGy/MBq. Total ab-
sorbed radiation doses at each Y-90 dose level are shown in Table
1. No additional toxicity due to the additional radiation was seen.
Engraftment: neutrophils 	0.5 by day 13.8 (range 11-22); plate-
lets 	50 by day 12.7 (range 10-22), no graft failures. In one
patient with myeloma, focal uptake of radiolabelled antibody was
seen at sites of disease activity suggesting in vivo targeting of
myeloma. This is consistent with our ﬁnding of CD66 antigen
expression by malignant plasma cells as shown by ﬂow cytometry.
There was a trend to greater disease response as the radiation dose
increased, with a greater proportion of patients at the higher
radiation dose levels achieving a CR. Conclusions: The radiola-
belled anti-CD66 monoclonal antibody showed consistently excel-
lent BM targeting and very low uptake by non-haematopoietic
organs. Up to 30 Gy of radiation was delivered to the BM with no
additional toxicity to other organs. Phase II studies are under way
using the Y-90-labelled anti-CD66 in RIC-allogeneic SCT proto-
cols and for autologous SCT for myeloma.
Table 1. Organ Dosimetry
Dose level
(MBqkg)
Organ Dose in (Gy)
Bone Marrow Liver Spleen
5 4.1 1.4 1.1
10 9.1 1.3 2.4
25 15.6 3.7 12.6
37.5 25.0 7.4 5.1
GVH/GVL
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PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE DESPITE COM-
PENSATORY FUNCTION OF LYMPHOID ORGANS IN VIVO
Beilhack, A.1, Schulz, S.1,2, Baker, J.1, Beilhack, G.F.1,
Nishimura, R.1, Landan, G.1, Baker, E.M.1, Herman, E.I.1,
Butcher, E.C.3, Contag, C.H.4, Negrin, R.S.1 1Division of Blood &
Marrow Transplantation, Stanford University, Stanford, CA; 2Institute
of Pathology, Technical University Munich, Germany; 3Department of
Pathology, Stanford University, Stanford, CA; 4Department of Pediat-
rics, Stanford University, Stanford, CA.
Acute graft-versus-host disease (aGVHD) results from allo-
reactive donor derived T cells attacking targets in the gastroin-
testinal tract, liver and skin. We observed the initiation and
rapid kinetics of aGVHD in a murine model [FVB/N (H-2q)
into irradiated BALB/c (H-2d)] using in vivo bioluminescence
imaging. The transition from the initiation to the effector phase
of aGVHD (day 3-4) was characterized by rapid T cell prolif-
eration and upregulation of gut homing receptors 
47, 
E7
and CCR9 on alloreactive T cells in Peyer’s patches (PP),
mesenteric lymph nodes (LN) and spleen, but not peripheral
LNs. Therefore we asked whether the lack of speciﬁc lymphoid
priming sites would lead to decreased alloreactive T cell inﬁl-
tration in the gut compared to the liver and skin. Using PP
deﬁcient mice, we observed that mesenteric LN and spleen
compensate for the lack of PP as alloreactive priming sites.
Transplantation of PP and LN deﬁcient mice (LT
/) showed
that the spleen alone was sufﬁcient to cause the complete proﬁle
of aGVHD with a time course similar to that of wild-type mice.
Splenectomized mice with intact secondary lymphoid organs
also developed aGVHD. Strikingly, treatment of splenecto-
mized recipients with blocking antibodies against the lymphoid
homing receptors l-selectin and MAdCAM-1 prevented GVHD
with 100% survival (	120 d, P  .0001). Our study shows that
multiple priming sites are involved in GVHD initiation, the
spleen compensating for the lack of PP and mesenteric LN, and
vice versa. In contrast, splenectomy and antibody blocking re-
sulted in a clear survival beneﬁt for all recipients. A.B. and S.S.
contributed equally to this study.
24
THE HAPLOIMMUNOSTORM SYNDROME: A DISTINCT CLINICAL ENTITY
SEEN IN HLA-HAPLOIDENTICAL CELLULAR IMMUNOTHERAPY
Colvin, G.A.1, Chung, S.1, Ballen, K.K.2, Dey, B.R.2, Winer, E.1,
Quesenberry, P.J.1 1Roger Williams Medical Center, Department of
Research, Adel Decof Cancer Center, Providence, RI; 2Massachusetts
General Hospital, Boston, MA.
An immune-mediated anti-tumor response is the ultimate goal of
allogeneic transplantation for relapsed, refractory malignancies.
We developed a transplant protocol with less toxicity compared
with standard allogeneic transplantation. We utilized multiple do-
nor lymphocyte infusions after nonmyeloablative HLA-haploiden-
tical stem cell transplantation for refractory disease. We have
performed a total of 41 HLA-mismatched transplants with escala-
tion of the CD3 dose to 2  108 cells/kg using G-CSF primed
product, with a conditioning regimen of 100 cGy total body irra-
diation. Our phase I/II study had 26 with hematologic malignan-
cies. This therapy results in loss of detectable macrochimerism.
Despite this, 13 responses, six major, occurred outside of macro-
chimerism. We have observed a new infusion related clinical entity
named haploimmunostorm (HIS), observed after infusion. This
syndrome occurred in 26 out of 30 (87%) patients with a CD3
dose more than 1  108 cells/kg. In the syndrome, a constellation
of symptoms occurred, some with variable penetrance, in which
hyperpyrexia and malaise were a constant feature occurring as early
as 4 hrs after cell infusion (median of 14 hrs). A morbilliform rash
was seen in 40% of patients. Biopsies revealed no evidence of
hyperacute or acute GVHD. Diarrhea was present in a 20% of
patients; biopsies taken also failed to show any evidence of GVHD.
Transient elevations of liver enzymes occurred in 40% of the
patients usually. Steroids were used successfully if the HIS syn-
drome lasted more than 72 hrs. We used a Bioplex machine and
analyzed 17 separate cytokine levels serially in these patients be-
ginning with pre-treatment levels. Cytokine level analysis showed
up to a 90 fold increase in baseline cytokine levels with signiﬁcant
increases of at least 10 fold in IFN-, IL-10, IL-13, IL-2, IL-5,
IL-6, IL-7, IL-8, MCP-1, and MIP-1. This syndrome appears to
be immunologically based and represents neither hyperacute nor
acute GVHD. This syndrome is different than an engraftment
syndrome reported in some patients undergoing autologous trans-
plant. Engraftment syndrome occurs at time of engraftment, op-
posed to HIS in which may be a rejection syndrome. Engraftment
syndrome is similar to HIS but deviates with presence of capillary
leak and pulmonary inﬁltrates. In summary, we have observed a
new clinical entity that was not previously seen and is a result of the
donors having a relatively intact immune system at the time of cell
infusion.
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STATISTICAL MODELLING FOR CLINICAL AND GENETIC RISK FACTORS
FOR GvHD AND SURVIVAL IN A COHORT OF EUROPEAN HLA MATCHED
SIBLING TRANSPLANTS
Dickinson, A.M.1, Holler, E.2, Rocha, V.3, Hromadnikova, I.4,
Sedlacek, P.4, Kolb, H.-J.5, Pearce, K.F.1 1University of Newcastle upon
Tyne, Newcastle upon Tyne, United Kingdom; 2University of Regens-
burg, Regensburg, Germany; 3Hopital Saint-Louis, Paris, France;
4Charles University, Prague, Czech Republic; 5Ludwig Maximillian
Universitat, Munchen, Germany.
A cohort of 244 HLA matched sibling transplants from 5
centres within Europe were typed for SNPs or microsatellites
(IL-1R
, IL-4, IL-6, IL-10, IFN, TNF
, TNFR11, and ste-
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